Skip to main content

Table 1 PROTECT Trial, post-hoc analysis of ITTIV population

From: Oral heparin: status review

ITTIV population N = 299 (includes all patients from USA, Canada/Australia)

Low dose oral-heparin (60,000 IU/1.5 g SNAC) 30 days)

High dose oral-heparin (90,000 IU/2.25 g SNAC) 30 days

Injectable LOVENOX ® 30 mg s.c b.i.d.)10-day followed by placebo (to day 30)

Total DVT rate

27%

18%

28%

Relative Risk Reduction

4%

55%